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Summary
Background:  Increased  mean  platelet  volume  is  a  central  process  in  the  pathophysiology  of
coronary  heart  disease.  Insulin  resistance  contributes  to  increased  platelet  activation.
Aim: To  assess  the  mean  platelet  volume  and  its  possible  relationship  with  insulin  resistance  in
non-diabetic  patients  with  slow  coronary  ﬂow.
Methods  and  subjects:  The  study  included  60  patients  with  slow  coronary  ﬂow  and  20  subjects
(controls)  with  normal  coronary  arteries.  Slow  coronary  ﬂow  patients  were  divided  into  2  groups,
insulin resistant  (32  patients)  and  insulin  sensitive  (28  patients)  according  to  the  homeostasis
model assessment  of  insulin  resistance  index  (HOMA-IR).
Results:  Patients  with  slow  coronary  ﬂow  had  signiﬁcantly  higher  mean  platelet  volume  values
(7.9 ±  0.47  vs.  7.1  ±  0.5,  p  <  0.01),  insulin  level  (10.8  ±  3.2  vs.  8.2  ±  1.4,  p  <  0.01),  and  HOMA-
IR scores  (2.72  ±  0.85  vs.  1.84  ±  0.19,  p  <  0.01).  These  parameters  were  signiﬁcantly  higher  in
insulin-resistant  patients  than  in  insulin-sensitive  ones.  The  mean  platelet  volume  was  cor-
related with  HOMA-IR  (r  =  0.52,  p  <  0.01)  and  insulin  level  (r  =  0.58,  p  <  0.01).  In  multivariate
analysis, mean  platelet  volume  and  HOMA-IR  were  independent  predictors  of  mean  TIMI  frame
count {(B  ±  SE  =  0.562  ±  2.95,  p  <  0.01)  and  (B  ±  SE  =  0.538  ±  2.46,  p  <  0.01),  respectively}.
Conclusion:  Patients  with  slow  coronary  ﬂow  have  increased  mean  platelet  volume  which  was
associated  with  insulin  resistance  in  non-diabetic  slow  coronary  ﬂow  patients.  TIMI  frame  counts
correlated  with  mean  platelet  volume  and  increased  insulin  resistance.  Thus,  insulin  resistance
and platelet  activity  may  have  a  role  in  the  pathogenesis  of  slow  coronary  ﬂow.  Also,  they  may
have a  possible  beneﬁt  as  follow
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Introduction
Coronary  slow  ﬂow  (CSF)  is  characterized  by  late  opaciﬁca-
tion  of  the  epicardial  coronary  arteries  without  occlusive
disease  [1].  The  exact  pathophysiologic  mechanisms  of
CSF  phenomenon  remain  uncertain.  Small  vessel  dysfunc-
tion  has  been  implicated  in  the  pathogenesis  of  CSF
phenomenon  since  its  ﬁrst  description  [2,3]. It  has  been
reported  that  coronary  endothelial  dysfunction  plays  an
important  pathogenetic  role  in  patients  with  CSF  [4].  In
addition,  platelet  function  disorders  have  also  been  sug-
gested  to  be  involved  in  the  development  of  CSF  [5].
Mean  platelet  volume  (MPV)  is  one  of  the  platelet  func-
tion  indices  that  reﬂects  the  platelet  production  rate  and
stimulation  [6].  It  has  been  reported  that  elevated  values
of  MPV  are  associated  with  various  cardiovascular  diseases
[7].  Elevated  values  of  MPV  are  considered  as  a  marker  of
increased  thromboembolic  risk  in  mitral  stenosis  patients
[8].
In  CSF  syndrome,  it  has  been  suggested  that  an  insulin-
resistant  state  may  lead  to  the  development  of  coronary
microvascular  dysfunction  before  the  development  of  overt
diabetes  mellitus  [9].  Insulin  resistance  is  associated  with
a  functional  change  in  platelets  that  promotes  thrombosis.
Decreased  vascular  endothelial  production  of  prostacyclin
and  nitric  oxide  in  patients  with  insulin  resistance  promotes
increased  activation  of  platelets  [10].
To the  best  of  our  knowledge,  no  study  has  investigated
speciﬁcally  the  direct  relationship  between  insulin  resis-
tance  and  MPV  in  non-diabetic  CSF  patients  to  advise  a
treatment  strategy  for  these  patients.  Accordingly,  the  aim
of  our  study  was  to  evaluate  the  relationship  between  MPV
and  insulin  resistance  in  non-diabetic  CSF  patients.
Patients and methods
Sixty  patients  with  CSF  as  evidenced  by  coronary  angio-
graphic  results  and  20  control  subjects  with  normal  coronary
arteries  were  included.  Patients  with  CSF  were  subdivided
into  two  groups  depending  on  the  presence  of  insulin
resistance,  an  insulin-resistant  group  (32  patients)  and  an
insulin-sensitive  group  (28  patients).
Exclusion  criteria  were  patients  with  known  coronary
artery  disease,  coronary  plaque  on  coronary  angiography,
peripheral  artery  disease,  valvular  heart  disease,  left  ven-
tricular  ejection  fraction  less  than  50%,  thrombocytopenia,
renal  and  hepatic  impairment,  chronic  inﬂammatory  dis-
ease,  malignancy,  thyroid  hormonal  dysfunction,  pregnancy,
septicemia,  cerebrovascular  accident,  uncontrolled  hyper-
tension,  and  treatment  for  hyperlipidemia.  To  avoid  the
inﬂuence  of  disturbances  in  insulin  secretion,  all  subjects
with  diabetes  mellitus  (fasting  glucose  >125  mg/dl  or  glucose
in  120  min  of  oral  glucose  tolerance  test  >200  mg/dl),  anti-
inﬂammatory  drugs  within  the  previous  3  months,  or  any
drugs  known  to  affect  carbohydrate  and  lipid  metabolism
were  excluded  from  this  study.  The  study  was  approved  by
the  basal  ethical  committee  of  our  hospital  and  all  patients
gave  written  consent.
Coronary  arteriography  was  performed  by  a  femoral
approach  using  the  standard  Judkins  technique  for  sub-
jects  who  suffered  from  angina  and  angina-like  symptoms
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shortness  of  breath,  palpitation,  etc.)  and  their  symptoms
ould  not  be  adequately  clariﬁed  with  non-invasive  tests.
low  coronary  ﬂow  and  thrombolysis  in  myocardial
nfarction frame  count
o  measure  coronary  blood  ﬂow,  the  time  elapsed  from
he  appearance  of  the  contrast  agent  until  it  reached  the
istal  end  of  either  left  anterior  descending  (LAD)  artery,
ircumﬂex  artery,  or  the  right  coronary  artery  in  terms  of
ine  frame  count  was  considered  to  be  the  thrombolysis
n  myocardial  infarction  (TIMI)  frame  count.  Distal  end  was
eﬁned  as  distal  bifurcation  for  LAD  and  circumﬂex  artery
nd  ﬁrst  branch  of  posterolateral  artery  for  right  coronary
rtery.  The  ﬁnal  count  was  subtracted  from  the  initial  count
nd  the  exact  TIMI  frame  count  was  calculated  for  the  given
rtery.  However,  it  was  divided  by  1.7  when  LAD  artery  was
he  case  for  adjusted  correction.  TIMI  frame  counting  was
one  by  two  separate  cardiologists.  The  cutoff  values  were
eﬁned  according  to  TIMI  frame  count  method  by  Gibson
t  al.  [11], 36.2  ±  2.6  frames  for  LAD,  22.2  ±  4.1  frames  for
ircumﬂex,  and  20.4  ±  3.0  frames  for  right  coronary  artery.
he  corrected  cutoff  value  for  LAD  coronary  artery  was
1.3  ±  1.5  frames.  Any  frame  count  above  these  thresholds
as  considered  CSF.
lood  samples  and  analysis
lood  samples  were  collected  from  the  patients  after  a
2  h  overnight  fasting.  All  routine  biochemical  tests  were
arried  out  on  an  autoanalyzer.  MPV  was  analyzed  using
lood  samples  with  K3  EDTA  that  were  analyzed  after  1  h
f  venipuncture  to  allow  stabilization  of  platelet  shape  and
o  prevent  EDTA-induced  swelling.  The  estimate  of  insulin
esistance  by  homeostasis  model  of  assessment  (HOMA-IR)
erives  an  estimate  of  insulin  sensitivity  from  the  mathemat-
cal  modeling  of  fasting  glucose  and  insulin  concentrations
10].  In  comparison  with  the  euglycemic  clamp,  the  HOMA-
R  model  is  an  easy,  practical,  and  inexpensive  method  for
ssessing  IR.  We  applied  the  HOMA-IR  in  non-diabetic  partic-
pants  using  the  following  formula  [12]; fasting  insulin  level
U/mL)  ×  fasting  glucose  (mg/dL)/405.  Subjects  whose
alues  exceeded  the  75th  percentile  (i.e.  2.0)  were  con-
idered  to  have  insulin  resistance  (HOMA-IR  index)  [13].
tatistical  analysis
ontinuous  variables  were  expressed  as  mean  ±  SD  and  cate-
orical  variables  are  expressed  as  percentages.  Comparison
f  variables  between  the  two  groups  was  performed  using
he  2 test  and  Student’s  t-test.  The  correlation  between
ean  TIMI  frame  count  and  MPV,  HOMA-IR,  and  other  mea-
urements  was  assessed  by  the  Pearson  correlation  analysis.
ultivariate  linear  regression  analysis  was  used  to  ﬁnd
he  signiﬁcant  independent  predictors  of  mean  TIMI  frame
ount.esults
emographic  and  clinical  characteristics  of  the  study  pop-
lation  are  presented  in  Table  1.  No  signiﬁcant  difference
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Table  1  Demographic  and  clinical  characteristics  of  the  study  population.
Group  I  Group  II  p-Value
Age  (years)  58.41  ±  6.53  56.84  ±  7.40  0.43
Pulse (beat/min)  71.70  ±  8.21  72.02  ±  6.81  0.71
Systolic blood  pressure  (mmHg)  133.74  ±  16.62  132.83  ±  14.61  0.25
Diastolic blood  pressure  (mmHg)  76.76  ±  12.63  75.80  ±  11.36  0.54
Fasting glucose  (mg/dL)  95.60  ±  11.82  90.22  ±  10.72  0.08
Hemoglobin  A1c,  (%)  5.32  ±  0.41  5.30  ±  0.36  0.22
HOMA-IR index 2.70  ±  0.85  1.84  ±  0.23  <0.01
Insulin level  (U/mL)  10.81  ±  3.27  8.21  ±  1.44  <0.05
Mean platelet  volume  (ﬂ) 7.90  ±  0.47  7.17  ±  0.52  <0.01
Hypertension 18 (30.00%)  7 (35.00%)  0.72
Triglycerides  (mg/dL) 130.33  ±  43.94  128.11  ±  40.43  0.64
Total cholesterol  (mg/dL)  179.85  ±  28.62  181.31  ±  19.80  0.56
HDL (mg/dL)  40.90  ±  6.53  41.45  ±  6.92  0.73
LDL (mg/dL)  91.44  ±  31.72  90.70  ±  29.81  0.81
Medications
ACE inhibitors 12 (20.00%)  5 (25.00%)  0.76
Beta-blockers 16 (26.66%)  6 (30.00%)  0.79
Calcium-channel  blockers 17 (28.33%)  5 (25.00%)  0.82
Statin 16 (26.66%)  6 (30.00%)  0.79
t; HD
w
r
l
l
P
aHOMA-IR, insulin resistance by homeostasis model of assessmen
angiotensin-converting enzyme.
as  found  between  patients  with  CSF  and  controls  with
espect  to  age,  sex,  body  mass  index  (BMI),  total  cholesterol,
ow-density  lipoprotein  cholesterol  (LDL-C),  high-density
ipoprotein  cholesterol  (HDL-C),  and  HbA1C  (all  p  >  0.05).
atients  with  CSF  had  higher  MPV  (ﬂ),  insulin  levels  (U/mL),
(
n
c
Table  2  The  clinical  and  laboratory  characteristics  of  the  insuli
ﬂow.
Insulin  resistant  (32
Age  57.52  ±  5.23  
Systolic BP  (mmHg)  140.42  ±  21.31  
Diastolic BP  (mmHg)  81.42  ±  10.13  
Hemoglobin  (g/dl)  14.12  ±  1.58  
Fasting blood  glucose  (mg/dL) 98.33  ±  14.91  
Body mass  index  (kg/m2)  30.14  ±  2.53  
Insulin level  (uU/mL) 11.81  ±  3.13  
Platelet count  (×103/L) 249.22  ±  74.25  
Platelet volume  (ﬂ)  8.25  ±  0.48  
WBCs (×103/L)  7.50  ±  2.34  
Triglycerides  (mg/dL)  131.10  ±  47.52  
Total cholesterol  (mg/dL)  188.03  ±  28.53  
LDL (mg/dL)  96.32  ±  26.22  
HDL (mg/dL)  40.80  ±  6.24  
Drugs: beta-blockers  8  (25.00%)  
Calcium-channel  blockers  10  (31.25%)  
Statins 8  (25.00%)  
ACE inhibitors  4  (12.50%)  
Aspirin 7  (21.87%)  
BP, blood pressure; WBC, white blood cell; LDL, low-density lipoprot
enzyme.L, high-density lipoprotein; LDL, low-density lipoprotein; ACE,
nd  HOMA-IR  index  compared  with  control  participants
p  <  0.01).
The  mean  TIMI  frame  count  was  found  to  be  sig-
iﬁcantly  higher  in  the  CSF  group  compared  with  the
ontrol  group  (52.6  ±  10.3  vs.  18.6  ±  3.3,  p  <  0.001).  Mean
n-resistant  and  insulin-sensitive  patients  with  coronary  slow
) Insulin  sensitive  (28) p-Value
54.84  ±  6.81  0.08
136.22  ±  4.92  0.28
78.11  ±  12.30  0.26
14.20  ±  1.41  0.63
90.24  ±  13.39  0.15
24.50  ±  2.82  <0.05
8.23  ±  1.57  <0.01
228.31  ±  61.45  0.21
7.55  ±  0.25  <0.01
7.36  ±  2.73  0.75
125.80  ±  42.79  0.66
176.89  ±  19.70  0.08
94.71  ±  27.12  0.82
43.70  ±  5.83  0.06
8  (28.57%)  0.75
7  (25.00%)  0.64
8  (28.57%)  0.75
8  (28.57%)  0.12
6  (21.42%)  0.96
ein; HDL, high-density lipoprotein; ACE, angiotensin-converting
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Figure  1  (a)  Correlation  between  mean  thrombolysis  in
myocardial  infarction  (TIMI)  frame  count  and  insulin  level.  (b)
Table  3  Correlation  of  mean  platelet  volume  (ﬂ)  with
other  parameters.
r  p-Value
HOMA-IR  0.52  <0.01
Insulin level  0.58  <0.01
Total cholesterol  0.14  >0.05
Triglycerides  0.15  >0.05
Fasting  blood  glucose  0.06  >0.05
Systolic  BP 0.19  >0.05
Diastolic  BP 0.17  >0.05
LVMI 0.37  <0.05
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aCorrelation  between  mean  TIMI  frame  count  and  insulin  resis-
tance by  homeostasis  model  of  assessment  (HOMA-IR).
TIMI  frame  count  was  signiﬁcantly  correlated  with  MPV
(ﬂ),  fasting  plasma  insulin  levels,  and  HOMA-IR  index
(r  =  0.6,  p  <  0.01,  r  =  0.43,  p  <  0.01,  r  =  0.49,  p  <  0.01,  respec-
tively)  (Fig.  1a,b  and  2).  At  multiple  regression  analysis
mean  TIMI  frame  count  correlated  independently  with  MPV
(B  ±  SE  =  0.562  ±  2.95,  t  =  5.66,  p  <  0.01)  and  HOMA-IR  index
(B  ±  SE  =  0.538  ±  2.46,  t  =  4.37,  p  <  0.01).
r =  0.6, P<0.01
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Figure  2  Correlation  between  mean  thrombolysis  in  myocar-
dial infarction  (TIMI)  frame  count  and  mean  platelet  volume.
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dHOMA-IR, insulin resistance by homeostasis model of assess-
ment; BP, blood pressure; LVMI, left ventricular mass index.
The  clinical  and  laboratory  characteristics  of  the
nsulin-resistant  and  insulin-sensitive  patients  with  CSF  are
resented  in  Table  2.  There  were  no  statistically  signiﬁcant
ifferences  between  the  two  groups  with  respect  to  age,
evels  of  glucose  (mg/dl),  WBCs,  total  cholesterol,  triglyc-
ride,  LDL-C,  or  HDL-C.  MPV  (ﬂ),  insulin  (U/mL)  and  body
ass  index  were  signiﬁcantly  higher  in  insulin-resistant  CSF
atients  than  in  insulin-sensitive  CSF  patients  (p  <  0.01  for
ll).  The  MPV  was  correlated  with  HOMA-IR  index  (r  =  0.52,
 <  0.01)  and  insulin  level  (r  =  0.58,  p  <  0.01)  (Table  3).
iscussion
he  present  study  investigated  the  relationship  between
PV  and  insulin  resistance  in  non-diabetic  patients  with
SF.  The  study  found  that  MPV  and  insulin  resistance  are
igher  in  CSF  patients.  MPV,  an  indicator  of  platelet  acti-
ation,  was  higher  in  insulin-resistant  CSF  patients  than  in
nsulin-sensitive  CSF  patients.
CSF  phenomenon  is  an  important  clinical  entity  because
t  may  be  the  cause  of  angina  at  rest  or  during  exercise,
cute  myocardial  infarction,  and  hypotension  [14—16].
However,  only  a  limited  number  of  studies  have  focused
n  the  etiology  of  this  unique  angiographic  phenomenon.
t  has  been  reported  that  coronary  endothelial  dysfunction
lays  an  important  pathogenetic  role  in  patients  with  CSF
4].  Moreover,  myocardial  biopsy  studies  have  also  revealed
he  presence  of  coronary  microvascular  disease  in  patients
xhibiting  CSF  [17]. Platelet  function  disorders  have  also
een  suggested  to  be  involved  in  the  development  of  CSF
s  the  platelet  aggregability  increased  in  patients  with  CSF
ompared  with  controls  [5]  suggesting  an  altered  platelet
eactivity  and  aggregation  which  may  require  effective  anti-
latelet  therapy  in  CSF  patients.  However,  the  association
f  MPV  with  insulin  resistance,  which  has  been  accepted
s  one  of  the  risk  factors  for  CAD,  has  gained  little  atten-
ion.
Platelets  play  an  important  role  in  the  integrity  of  normal
omeostasis,  and  MPV  is  the  indicator  for  its  function  and
ctivity  [18]. The  large  platelets  having  dense  granules  are
ore  active  biochemically,  functionally,  and  metabolically,
ave  higher  thromboxane  A2  levels,  express  more  glycopro-
ein  Ib  and  IIb/IIIa  receptors,  and  could  be  a risk  factor  for
eveloping  coronary  thrombosis  [18,19].
1p
i
M
w
a
r
a
i
r
i
t
i
c
u
c
w
b
i
B
p
e
p
d
i
e
p
n
b
M
i
e
p
i
r
t
r
a
D
a
i
i
o
I
t
a
l
[
s
s
T
D
s
f
p
e
f
C
M
p
t
T
M
M
f
A
W
l
R
[
[
[
[80  
The  present  study  showed  that  MPV  increased  in  CSF
atients  compared  with  the  control  group.  In  addition,  a  pos-
tive  correlation  was  found  between  TIMI  frame  count  and
PV.  In  previous  reports,  there  are  different  methods  that
ere  used  for  the  analyses  of  platelet  activation;  optical
ggregometry,  platelet  function  analyzer  (PFA-100),  platelet
eactivity  test,  platelet  aggregate  ratio,  ﬂow  cytometry,
nd  thromboxane  B2 generation  [20]. All  tests  have  lim-
tations  in  their  use  due  to  complex  pre-analytic  factors,
educed  speciﬁcity,  and  poor  reproducibility.  However,  MPV
s  a  simple  marker,  not  requiring  an  advanced  or  expensive
echnology  [20].
The  present  study  showed  that  insulin  resistance
ncreased  in  CSF  patients  compared  to  control  with  signiﬁ-
ant  positive  correlation  with  TIMI  frame  count.  The  study
sed  the  HOMA-IR  to  estimate  insulin  sensitivity.
Ozcan  et  al.  found  that  in  patients  with  CSF,  TIMI  frame
ounts  and  high  sensitivity  C-reactive  protein  are  correlated
ith  increased  insulin  resistance  (HOMA-IR)  and  thus,  it  can
e  suggested  that  insulin  resistance  and  inﬂammation  may,
n  part,  have  a  role  in  the  pathogenesis  of  CSF  [21]. Also,
inak  et  al.  [9]  investigated  impaired  glucose  tolerance  in
atients  with  CSF  and  suggested  that  impaired  glucose  tol-
rance  may  be  an  independent  etiological  factor  for  CSF
henomenon.  On  the  basis  of  these  ﬁndings  and  literature
ata,  it  can  be  suggested  that  an  insulin-resistant  state  may,
n  part,  play  a  role  in  the  pathogenesis  of  CSF.
Recently,  Varol  et  al.  showed  that  MPV  was  signiﬁcantly
levated  in  insulin-resistant,  non-obese,  non-diabetic  CAD
atients  when  compared  to  insulin-sensitive,  non-obese,
on-diabetic  CAD  patients  [22].
The  present  study  investigated  the  direct  relationship
etween  insulin  resistance  and  MPV  in  patients  with  CSF.
PV  was  higher  in  insulin-resistant  patients  with  CSF  than
n  insulin-sensitive  CSF  patients.  In  another  study,  Yazici
t  al.  found  that  MPV  values  were  signiﬁcantly  higher  in
atients  with  insulin  resistance  than  in  patients  without
nsulin  resistance  in  prehypertension  subjects  [23]. Insulin
esistance  is  associated  with  a  functional  change  in  platelets
hat  promotes  thrombosis  [24]. In  conditions  of  insulin
esistance,  a  reduction  in  platelet  sensitivity  to  the  anti-
ggregating  effects  of  insulin  has  been  reported  [5,25,26].
ecreased  vascular  endothelial  production  of  prostacyclin
nd  nitric  oxide  in  patients  with  insulin  resistance  promotes
ncreased  activation  of  platelets  [10]. Another  mechanism
s  the  increased  platelet  reactivity  due  to  the  direct  effect
f  hyperglycemia  via  osmotic  effects  on  platelets  [27].
nsulin  resistance,  diabetes  mellitus,  and  other  risk  fac-
ors  associated  with  endothelial  dysfunction  might  trigger
 series  of  cytokine  production  which  in  turn  may  stimu-
ate  the  production  of  large  platelets  in  the  bone  marrow
28].
The  present  study  was  limited  by  the  small  sample
ize.  Also,  the  effect  of  the  volume,  rate,  and  pres-
ure  of  the  contrast  injection  on  the  measurement  of
IMI  frame  count  should  be  considered  as  a  limitation.
ata  evaluating  inﬂammatory  parameters  such  as  high-
ensitivity  C-reactive  protein  and  evaluating  endothelial
unction  such  as  ﬂow-mediated  vasodilatation  were  not
erformed.  Further  research  with  a  large  sample  size  to
valuate  high-sensitivity  C-reactive  protein  and  endothelial
unction  is  recommended.
[I.A.  Elsherbiny  et  al.
onclusion
PV  and  insulin  resistance  increased  in  CSF  non-diabetic
atients.  In  the  light  of  these  ﬁndings,  it  can  be  suggested
hat  they  may,  in  part,  have  a  role  in  the  pathogenesis  of  CSF.
here  is  a  close  relationship  between  insulin  resistance  and
PV.  We  can  establish  the  clinical  signiﬁcance  of  increased
PV  in  CSF.  MPV  and  HOMA-IR  may  have  possible  beneﬁt  as
ollow-up  markers  during  the  management  of  CSF  patients.
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